Last mentioned: Mar 19, 2026
Earnings Call
Management hosts a conference call to discuss 2025 performance and 2026 outlook.
Financial Reporting
XOMA files Q4 and Full Year 2025 financial results with the SEC.
Asset Acquisition
Completion of a significant acquisition of royalty rights from a clinical-stage partner.
Strategic Disclosure
XOMA issues Regulation FD disclosure regarding portfolio updates.
XOMA Royalty reported its Q4 and full-year 2025 financial results, highlighting a significant expansion of its royalty portfolio and the continued commercial success of key assets like Vabysmo and Daybue. The company remains focused on its strategic pivot toward becoming a pure-play royalty aggregator in the biotechnology sector.
Zevra Therapeutics has appointed Justin Renz as its new Chief Financial Officer, bringing over 20 years of biotech leadership to the rare disease specialist. The move comes as Zevra prioritizes the commercial rollout of Miplyffa, its recently FDA-approved treatment for Niemann-Pick disease type C.